



Christopher Halliday

Principal

chris.halliday@offitkurman.com

Philadelphia, PA – 267.338.1327

With over 25 years of experience at the intersection of innovation and law, patent attorney Chris Halliday is a recognized leader in patent prosecution, transactions, and corporate diligence within the life sciences sector.

Chris leverages his extensive background to deliver strategic intellectual property counsel to companies ranging from emerging life science biotech and medtech firms to global pharmaceutical giants. His practice is rooted in guiding clients through the complexities of patent prosecution, particularly in biologics, pharmaceuticals, and medical devices. His deep understanding of the life sciences ecosystem enables him to anticipate challenges and craft comprehensive IP strategies that align with business objectives, protect innovation, and maximize market exclusivity.

He also regularly advises on IP-driven transactions, including mergers, acquisitions, and licensing agreements, ensuring that his clients' intellectual assets are safeguarded and optimized for commercial success. Chris also plays a pivotal role in corporate due diligence, helping investors and companies navigate the risks and opportunities associated with high-value acquisitions and investments. His ability to distill complex scientific concepts into actionable legal strategies has earned him the trust of both R&D-driven enterprises and major venture capital firms. Chris' collaborative approach extends across Offit Kurman's network, allowing him to provide seamless support for multinational clients facing cross-border IP challenges. His commitment to staying at the forefront of technological advancements, coupled with his strategic insight, positions him as a go-to advisor for life sciences innovators looking to protect and capitalize on their intellectual property.

He is a sought-after speaker on patent law trends in life sciences and regularly contributes to leading legal and industry publications.

Education

- University of New Hampshire Franklin Pierce School of Law (LL.M.)
 - Intellectual Property

Services

- Intellectual Property
- Patents
- Business Advisory and Outside General Counsel

- Temple University Beasley School of Law (LL.M.)
 - Trial Advocacy
- University of New Hampshire Franklin Pierce School of Law (J.D.)
- Pennsylvania State University (B.S.)
 - Chemical Engineering
- Pennsylvania State University (B.S.)
 - Biochemistry

State Bar Admissions

- Pennsylvania
- U.S. Virgin Islands

Court Admissions

- United States Patent and Trademark Office

Professional Affiliations

- Member, Engineering Advisory Committee Board for Penn State University
- Member, Advisory Board for Penn State Brandywine
- Member, Advisory Board for the University of the Virgin Islands

Recognitions

- Legal 500 Philadelphia Elite for Intellectual Property, 2025
- Practice Group of the Year, Intellectual Property, Law360, 2019
- Litigation Department of the Year–Intellectual Property, The American Lawyer, 2019

Representative Matters

•

A US pharmaceutical company in its acquisition of a biopharmaceutical company focused on the development of a clinical-stage investigational therapy for orphan metabolic diseases.

•

A specialty pharmaceutical company in its agreement with a multinational pharmaceutical and biotechnology corporation to develop a combination drug device overdose rescue pen under which the multinational pharmaceutical and biotechnology corporation will develop and commercialize the product in the United States and the specialty pharmaceutical company will receive royalties on net sales.

•

A specialty pharmaceutical company in its agreement with a biotech company for the development of a novel drug device combination product to be developed for the treatment

of suspected acute myocardial infarction.

•

A pharmaceutical company in its US\$5.76 billion strategic collaboration with a Japanese pharmaceutical company for the worldwide co-development and co-commercialization of an anti-cancer medication.

•

A clinical-stage biotechnology company in its US\$1.37 billion deal with a pharmaceutical company for a new approach to immuno-oncology where the pharmaceutical company is putting up US\$125 million for an upfront and near-term milestones in a collaboration deal embedded with US\$1 billion in development milestones and another US\$250 million for each new therapy that manages to receive approval. They will jointly develop anticancer cell therapies that trigger antitumor responses with cell therapies that can target antigens that are beyond the reach of other cell-based adoptive immunity strategies.

•

An American pharmaceutical company in its agreement with a clinical-stage biopharmaceutical company for the discovery and development of immuno-oncology therapies to discover novel cancer targets utilizing the clinical-stage biopharmaceutical company's proprietary FIND-IO platform. Under the term of the agreement, they will each receive options to exclusively license antibodies resulting from the collaboration.

•

A pharmaceutical company in its US\$50 million product financing agreement with an affiliate of an investment company, for the continued development of five differentiated, sterile injectable products.

•

An American biotechnology company in its US\$1 billion agreement with a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system and liver.

•

A pharma company in the implementation of an IP program and in its acquisition by a multinational pharmaceutical and biotechnology company.

•

Many small, midsize and multinational companies in the life sciences, technology and financial services sector in establishing and implementing their intellectual property.

•

A clinical-stage biotechnology company in the implementation of an IP program and in its acquisition by an American multinational pharmaceutical company.

-

A clinical-stage drug development company in implementation of an IP program, as well as an acquisition of a UK-founded, Jersey-registered, specialty biopharmaceutical company.

-

A company that designs and develops cloud-based healthcare software solutions in its US\$60 million initial public offering.

-

A medical device company in litigation in the Western District of Washington resulting in a favorable settlement.

-

A public land-grant research university in developing and attending its proof-of-concept program.

Offit Kurman Blogs

April 6, 2026

USPTO Issues Final Rule Requiring U.S.-Registered Patent Practitioner Representation for Foreign Applicants and Patent Owners

The United States Patent and Trademark Office (USPTO) has issued a Final Rule , published March 20, 2026, requiring all foreign-domiciled patent applicants, inventors, and patent owners to be represented by a U.S.-registered patent attorney (a lawyer who has passed...